Literature DB >> 16551211

Dry powder aerosol delivery systems: current and future research directions.

Hak-Kim Chan1.   

Abstract

Development of dry powder aerosol delivery system involves powder production, formulation, dispersion, delivery, and deposition of the powder aerosol in the airways. Insufficiency of conventional powder production by crystallization and milling has led to development of alternative techniques. Over the last decade, performance of powder formulations has been improved significantly through the use of engineered drug particles and excipient systems which are (i) of low aerodynamic diameters (being porous or of low particle density), and/or (ii) less cohesive and adhesive (via corrugated surfaces, low bulk density, reduced surface energy and particle interaction, hydrophobic additives, and fine carrier particles). Early insights into particle forces and surface energy that help explain the improvement have been provided by analytical techniques such as the atomic force microscopy (AFM) and inverse gas chromatography (IGC). Relative humidity is critical to the performance of dry powder inhaler (DPI) products via capillary force and electrostatic interaction. Electrostatic charge of different particle size fractions of an aerosol can now be measured using a modified electrical low-pressure impactor (ELPI). Compared with powders, much less work has been done on the inhaler devices at the fundamental level. Most recently, computational fluid dynamics has been applied to understand how the inhaler design (such as mouthpiece, grid structure, air inlet) affects powder dispersion. The USP throat is known to under-represent the oropharyngeal deposition of DPI aerosols. Studies using magnetic resonance imaging (MRI) model casts have been undertaken to explain the inter- and intra- subject variation in oropharyngeal deposition. Most of the lung deposition studies performed on commercial products did not allow a thorough understanding of the determinants affecting in vivo lung deposition. A more systematic approach would be necessary to build a useful database on the dependence of lung deposition on the breathing parameters, inhaler design, and powder formulation properties.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16551211     DOI: 10.1089/jam.2006.19.21

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  14 in total

1.  New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.

Authors:  Christophe Duret; Nathalie Wauthoz; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Pharm Res       Date:  2012-05-30       Impact factor: 4.200

Review 2.  Particle engineering for pulmonary drug delivery.

Authors:  Albert H L Chow; Henry H Y Tong; Pratibhash Chattopadhyay; Boris Y Shekunov
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

3.  Multi-scale modelling of powder dispersion in a carrier-based inhalation system.

Authors:  Zhenbo Tong; Hidehiro Kamiya; Aibing Yu; Hak-Kim Chan; Runyu Yang
Journal:  Pharm Res       Date:  2014-12-17       Impact factor: 4.200

4.  Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals.

Authors:  Phillip G Durham; Shumaila N Hanif; Lucia Garcia Contreras; Ellen F Young; Miriam S Braunstein; Anthony J Hickey
Journal:  J Vis Exp       Date:  2017-03-30       Impact factor: 1.355

5.  Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).

Authors:  Qi Tony Zhou; Zhenbo Tong; Patricia Tang; Mauro Citterio; Runyu Yang; Hak-Kim Chan
Journal:  AAPS J       Date:  2013-02-01       Impact factor: 4.009

6.  Development of a New Inhaler for High-Efficiency Dispersion of Spray-Dried Powders Using Computational Fluid Dynamics (CFD) Modeling.

Authors:  Worth Longest; Dale Farkas
Journal:  AAPS J       Date:  2019-02-07       Impact factor: 4.009

7.  Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols.

Authors:  P Worth Longest; Yoen-Ju Son; Landon Holbrook; Michael Hindle
Journal:  Pharm Res       Date:  2013-03-08       Impact factor: 4.200

8.  Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.

Authors:  Hanne Kinnunen; Gerald Hebbink; Harry Peters; Jagdeep Shur; Robert Price
Journal:  AAPS PharmSciTech       Date:  2014-05-16       Impact factor: 3.246

9.  Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.

Authors:  Srinivas R B Behara; Dale R Farkas; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2013-08-16       Impact factor: 4.200

Review 10.  Are inhaled systemic therapies a viable option for the treatment of the elderly patient?

Authors:  Stephen Allen
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.